New and emerging therapies for systemic lupus erythematosus

被引：1

作者：

Papachristodoulou, Eleni ^{[1
]}

Kyttaris, Vasileios C. ^{[1
]}

机构：

[1] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Rheumatol, 110 Francis St,Suite 4B, Boston, MA 02215 USA

来源：

CLINICAL IMMUNOLOGY | 2024年 / 263卷

关键词：

Systemic lupus erythematosus; Treatment; BLyS; Interferon; B cells; MESENCHYMAL STEM-CELL; PLACEBO-CONTROLLED TRIAL; RANDOMIZED DOUBLE-BLIND; REGULATORY T-CELLS; MYCOPHENOLATE-MOFETIL; MONOCLONAL-ANTIBODY; DISEASE-ACTIVITY; B-CELL; RHEUMATOID-ARTHRITIS; N-ACETYLCYSTEINE;

D O I：

10.1016/j.clim.2024.110200

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Systemic Lupus Erythematosus (SLE) and lupus nephritis treatment is still based on non-specific immune suppression despite the first biological therapy for the disease having been approved more than a decade ago. Intense basic and translational research has uncovered a multitude of pathways that are actively being evaluated as treatment targets in SLE and lupus nephritis, with two new medications receiving FDA approval in the last 3 years. Herein we provide an overview of targeted therapies for SLE including medications targeting the B lymphocyte compartment, intracellular signaling, co-stimulation, and finally the interferons and other cytokines.

引用

页数：20

共 236 条

[1] Effects of N-acetylcysteine on systemic lupus erythematosus disease activity and its associated complications: a randomized double-blind clinical trial study [J].

Abbasifard, Mitra ;

Khorramdelazad, Hossein ;

Rostamian, Abdolrahman ;

Rezaian, Mohsen ;

Askari, Pooya Saeed ;

Sharifi, Gholamhosein Taghipur Khajeh ;

Parizi, Moein Kardoust ;

Sharifi, Mobina Taghipour Khajeh ;

Najafizadeh, Seyed Reza .

TRIALS, 2023, 24 (01)

[2]

Alexander T, 2023, ANN RHEUM DIS, V82, P1459, DOI [10.1136/annrheumdis-2023-eular.5684, 10.1136/ard-2023-224152]

[3] The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus [J].

Alexander, Tobias ;

Sarfert, Ramona ;

Klotsche, Jens ;

Kuehl, Anja A. ;

Rubbert-Roth, Andrea ;

Lorenz, Hannes-Martin ;

Rech, Juergen ;

Hoyer, Bimba F. ;

Cheng, Qingyu ;

Waka, Aderajew ;

Taddeo, Adriano ;

Wiesener, Michael ;

Schett, Georg ;

Burmester, Gerd-Ruediger ;

Radbruch, Andreas ;

Hiepe, Falk ;

Voll, Reinhard E. .

ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (07) :1474-1478

[4] Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus- host disease [J].

Ali, Faraat ;

Ilyas, Anam .

CURRENT RESEARCH IN TRANSLATIONAL MEDICINE, 2022, 70 (03)

[5] Update on the Efficacy and Safety Profile of Voclosporin: An Integrated Analysis of Clinical Trials in Lupus Nephritis [J].

Arriens, Cristina ;

Teng, Y. K. Onno ;

Ginzler, Ellen M. ;

Parikh, Samir V. ;

Askanase, Anca D. ;

Saxena, Amit ;

Gibson, Keisha ;

Caster, Dawn J. ;

Atsumi, Tatsuya ;

Lisk, Laura ;

Randhawa, Simrat ;

Gluck, Rashieda ;

Solomons, Neil ;

Huizinga, Robert B. .

ARTHRITIS CARE & RESEARCH, 2023, 75 (07) :1399-1408

[6] Treatment of Lupus Nephritis With Abatacept [J].

Askanase, Anca D. ;

Byron, Margie ;

Keyes-Elstein, Lynette L. ;

Cagnoli, Patricia C. ;

McCune, W. Joseph ;

Chatham, W. Winn ;

Contreras, Gabriel ;

Daikh, David I. ;

Dall'Era, Maria ;

Wofsy, David ;

Davidson, Anne ;

Diamond, Betty ;

Mackay, Meggan ;

Ding, Linna ;

Gao, Wendy ;

Dooley, Mary Anne ;

Fragoso-Loyo, Hilda ;

Sanchez-Guerrero, Jorge ;

Karp, David R. ;

Olsen, Nancy J. ;

Jolly, Meenakshi ;

Kalunian, Kenneth ;

Kamen, Diane ;

Lee, Iris ;

Levesque, Marc C. ;

Lim, S. Sam ;

Ramos-Remus, Cesar ;

Rovin, Brad H. ;

Sayre, Peter H. ;

Smilek, Dawn E. ;

Tosta, Patti ;

Utset, Tammy O. ;

Venuturupalli, Swamy ;

Winchester, Robert .

ARTHRITIS & RHEUMATOLOGY, 2014, 66 (11) :3096-3104

[7] Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis [J].

Atisha-Fregoso, Yemil ;

Malkiel, Susan ;

Harris, Kristina M. ;

Byron, Margie ;

Ding, Linna ;

Kanaparthi, Sai ;

Barry, William T. ;

Gao, Wendy ;

Ryker, Kristin ;

Tosta, Patti ;

Askanase, Anca D. ;

Boackle, Susan A. ;

Chatham, W. Winn ;

Kamen, Diane L. ;

Karp, David R. ;

Kirou, Kyriakos A. ;

Sam Lim, S. ;

Marder, Bradley ;

McMahon, Maureen ;

Parikh, Samir V. ;

Pendergraft, William F., III ;

Podoll, Amber S. ;

Saxena, Amit ;

Wofsy, David ;

Diamond, Betty ;

Smilek, Dawn E. ;

Aranow, Cynthia ;

Dall'Era, Maria .

ARTHRITIS & RHEUMATOLOGY, 2021, 73 (01) :121-131

[8] IL-10 Production Is Critical for Sustaining the Expansion of CD5+ B and NKT Cells and Restraining Autoantibody Production in Congenic Lupus-Prone Mice [J].

Baglaenko, Yuriy ;

Manion, Kieran P. ;

Chang, Nan-Hua ;

Gracey, Eric ;

Loh, Christina ;

Wither, Joan E. .

PLOS ONE, 2016, 11 (03)

[9] Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy [J].

Baker, Matthew ;

Chaichian, Yashaar ;

Genovese, Mark ;

Derebail, Vimal ;

Rao, Panduranga ;

Chatham, Winn ;

Bubb, Michael ;

Lim, Sam ;

Hajian, Hooman ;

Gurtovaya, Oksana ;

Patel, Uptal ;

Tumlin, James .

RMD OPEN, 2020, 6 (03)

[10] Successful treatment of class V+IV lupus nephritis with multitarget therapy [J].

Bao, Hao ;

Liu, Zhi-Hong ;

Xie, Hong-Lang ;

Hu, Wei-Xin ;

Zhang, Hai-Tao ;

Li, Lei-Shi .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 19 (10) :2001-2010

← 1 2 3 4 5 6 7 8 9 10 →